A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Research highlights media misrepresentation of COVID-19 drug efficacy. ... For the study, the researchers conducted an analysis of 479 reports of hydroxychloroquine, ...

Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its ...

Ahead of a U.S Food and Drug Administration advisory panel meeting, drugmaker Merck has revealed final analysis data from a Phase 3 trial testing its oral antiviral pill against COVID-19.

However, the efficacy estimates of the COVID-19 vaccines from the trials mentioned above were much higher than the FDA and WHO threshold. In all the different trials, different factors have been ...

The updated trial analysis (ClinicalTrials.gov Identifier: NCT04575597) included 1433 adults with mild to moderate COVID-19 with symptom onset within 5 days of randomization.

Additional efficacy assessments were the prevention of severe or moderate-to-severe Covid-19 (a post hoc analysis), viral load at diagnosis, and variant-specific efficacy.

P axlovid, Pfizer’s pill to treat Covid-19, retained its 89% efficacy at preventing hospitalization and death in the full results of a study of 2,246 high-risk patients, the company said Tuesday ...

AstraZeneca said its latest figure on the vaccine’s efficacy was based on an analysis of 190 cases of symptomatic Covid-19 in the trial, 49 more cases than the company had analyzed earlier ...

The Food and Drug Administration released an analysis of Johnson & Johnson's COVID-19 vaccine Wednesday morning that appears to support its authorization for emergency use.